Soleno Therapeutics, Inc. SLNO
At closeMay 15, 2026, 4:00 PM EDT
After hours · May 15, 4:00 PM ET
52-week range unavailable
- YTD
- +14.49%
- 1 year
- -29.33%
- Market cap
- 2.76B
- Profit margin
- 33.70%
- YTD return
- +14.49%
- 1-year return
- -29.33%
- Volume
- 4.97M
- Open
- 52.99
- Previous close
- 53.01
- Day's range
- 52.98 – 53.01
- Earnings date
- Aug 5, 2026
Key statistics
- Enterprise value
- 2.63B
- PEG ratio
- 0.02
- Price / sales
- 0.00
- Price / book
- 5.57
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Total cash
- 0
- Total debt
- 0
- Return on equity
- 22.86%
- 50-day average
- 0.00
- 200-day average
- 0.00
Analyst view
- Strong buy5
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 5, 2026
Expected Aug 5, 2026. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 5, 2026 | Jun 30, 2026 | 0.91 | — | — | — |
| May 7, 2026 | Mar 31, 2026 | 0.73 | 0.59 | -0.14 | -19.18% |
| Feb 25, 2026 | Dec 31, 2025 | 0.64 | 0.80 | +0.16 | +25.00% |
| Nov 4, 2025 | Sep 30, 2025 | 0.0575 | 0.47 | +0.41 | +717.39% |
| Aug 6, 2025 | Jun 30, 2025 | -0.53 | -0.09 | +0.44 | +83.02% |
| May 7, 2025 | Mar 31, 2025 | -1.14 | -0.95 | +0.19 | +16.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 17, 2026 | Wells Fargo | down | Overweight | Equal-Weight |
| Apr 8, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Apr 7, 2026 | TD Cowen | down | Buy | Hold |
| Apr 7, 2026 | Wolfe Research | down | Outperform | Peer Perform |
| Apr 6, 2026 | Cantor Fitzgerald | down | Overweight | Neutral |
| Mar 18, 2026 | Oppenheimer | main | Outperform | Outperform |
About Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc. (SLNO) operates as a clinical-stage biopharmaceutical company, specializing in the creation and market introduction of groundbreaking treatments for uncommon illnesses. The cornerstone of its therapeutic pipeline is Diazoxide Choline Controlled-Release, a once-daily oral tablet aimed at addressing Prader-Willi Syndrome, currently progressing through an active Phase III clinical evaluation. Established in 1999, the Redwood City, California-headquartered firm adopted its current name, Soleno Therapeutics, Inc., in May 2017, having previously operated as Capnia, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- US
- Employees
- 115
- Website
- soleno.life
News
This Soleno Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday 
9 Health Care Stocks With Whale Alerts In Today's Session 
S&P 500 Gains For Fourth Session On Ceasefire Hopes: Fear & Greed Index Remains In 'Extreme Fear' Zone 
12 Health Care Stocks Moving In Monday's Intraday Session 
Gold Edges Higher; ISM Services PMI Falls In March 
Soleno Therapeutics, Playtika Holding And Other Big Stocks Moving Higher On Monday 
Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market 
12 Health Care Stocks Moving In Monday's Pre-Market Session 
Why Applied Optoelectronics Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket 
Earnings Scheduled For February 25, 2026
Your note
Sign in to keep a note on SLNO — it syncs with the Stock Master app.